探索导致Gaucher病单细胞骨质细胞激活的病理生理级联,通过CRISPR/Cas9技术生成
Maximiliano Emanuel Ormazabal1,2, Eleonora Pavan1, Emilio Vaena2
1Regional Coordinator Centre for Rare Diseases, Academic Hospital of Udine, 33100 Udine, Italy.
International journal of molecular sciences
|July 14, 2023
概括
氏病 (GD) 骨病理包括骨质结晶生成的增加. 一个新的GD单细胞模型 (GBAKO-THP1) 显示了这种潜力,这种潜力被疗法逆转,验证了其用于药物查的用途.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 细胞生物学 细胞生物学
背景情况:
- 氏病 (GD) 源于*GBA1*的致病变体,导致β-葡萄糖脑酶 (GCase) 缺乏和脂积累.
- 骨并发症,包括骨形成受损和吸收增加,在GD患者中是显著的.
- 目前的疗法不能完全解决GD骨病理,需要更好的疾病模型.
研究的目的:
- 描述一种新型的GD单细胞同源细胞模型 (GBAKO-THP1).
- 调查GD单细胞对骨质细胞形成和骨病理学的贡献.
- 用这种细胞模型评估各种化合物的治疗潜力.
主要方法:
- 使用基因编辑开发一个GBA1-null人类单细胞细胞系 (GBAKO-THP1).
- 评估促炎性细胞因子释放 (IL-1β,TNF-α) 和骨质细胞形成的标志物.
- 用复合GCase,基质合成酶抑制剂,药理伴随剂和抗炎药物治疗GBAKO-THP1细胞.
主要成果:
- 在GBAKO-THP1细胞中,呈现出较高的炎症前导细胞因子释放和增强的骨质结晶生成.
- GD单细胞表现出内在增加的骨质结晶性潜力.
- 治疗干预部分恢复了细胞因子的产生和骨质细胞形成.
结论:
- GBAKO-THP1模型准确地反映了GD单细胞功能障碍和骨质细胞生成.
- 该模型适用于针对各种机制的高通量选GD疗法.
- 研究结果提供了GD病变的洞察力,特别是骨质疾病中骨质结晶形成的恶化.
更多相关视频
相关概念视频
CRISPR
52.4K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
52.4K
CRISPR/Cas9 Genome Editing
72
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
72


